By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


SAGE Therapeutics 

29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: n/a Fax: n/a



Start Up

Company News
SAGE Therapeutics (SAGE) Announces Expedited Development Plan For SAGE-547 In The Treatment Of Postpartum Depression Based On FDA Breakthrough Therapy Meeting 12/6/2016 12:34:25 PM
SAGE Therapeutics (SAGE) Soars on Expedited Development of SAGE-547 Following Meeting With the FDA 12/6/2016 7:16:08 AM
SAGE Therapeutics (SAGE) Release: SAGE-547 Granted PRIME Designation By EMA For The Treatment Of Postpartum Depression 11/16/2016 10:34:30 AM
SAGE Therapeutics (SAGE) To Report Third Quarter 2016 Financial Results On Thursday, November 3, 2016 10/28/2016 12:19:04 PM
SAGE Therapeutics (SAGE) And Collaborators Publish New Pre-Clinical Data In Neuropharmacology Demonstrating A Novel Metabotropic Mechanism Of Sage 10/20/2016 1:04:55 PM
SAGE Therapeutics (SAGE) Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The MarcĂ© Society For Perinatal Mental Health Biennial Scientific Meeting 9/27/2016 11:04:46 AM
SAGE Therapeutics (SAGE) To Present At The Neurocritical Care Society 14th Annual Meeting 9/16/2016 11:01:01 AM
SAGE Therapeutics (SAGE) Announces Pricing Of Public Offering Of Common Stock 9/9/2016 10:55:26 AM
SAGE Therapeutics (SAGE) Announces Proposed Public Offering Of Common Stock 9/8/2016 10:57:48 AM
SAGE Therapeutics (SAGE) Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression 9/6/2016 11:33:54 AM